Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

2(40.0%)

N/A

2(40.0%)

Phase 4

1(20.0%)

5Total

Phase 2(2)

N/A(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07490990Not Yet Recruiting

A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure

Role: collaborator

NCT07336927Not ApplicableNot Yet Recruiting

IAT-MeVO Trial Domain Within the ACT-GLOBAL Adaptive Platform Trial

Role: collaborator

NCT06201455Not ApplicableRecruiting

Evaluation of Phacogoniotomy in Medically-controlled POAG

Role: collaborator

NCT06501651Phase 4Not Yet Recruiting

Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy

Role: collaborator

NCT05900921Phase 2Unknown

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

Role: collaborator

NCT01933204Phase 2Completed

Acupuncture for Relieving Perimenopausal Symptoms

Role: collaborator

All 6 trials loaded